相关实验视频

Updated: Feb 27, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

亚ليل选择性·维勒布兰德因子静音化

Jeroen Eikenboom¹, Noa Linthorst¹, Yvonne Jongejan¹

¹Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.

Research and practice in thrombosis and haemostasis

|February 26, 2026

概括

·维尔布兰德因子 (VWF) 的代基选择性沉默为·维尔布兰德病 (VWD) 和血栓性疾病提供了一个有前途的治疗策略. 这种方法使VWF水平正常化,改善VWD表型,减少血栓形成风险,而不会导致过度出血.

科学领域:

血液静止和血栓形成研究
分子医学是分子医学.
基因治疗的基因疗法

背景情况:

·威尔布兰德因子 (VWF) 在血液静止中至关重要,缺陷导致·威尔布兰德病 (VWD),高水平与血栓形成风险有关.
目前对VWD和血栓性疾病的治疗有局限性,需要新的治疗策略.

研究的目的:

审查对等位基选择性VWF抑制的概念,应用和可行性.
讨论VWF沉默作为治疗VWD和血栓性疾病的治疗方法的潜力.

主要方法:

利用小干扰RNAs (siRNAs) 以基于单核酸差异选择性地沉默一个VWF等位基.
在体外和体内生物模型中评估异位素选择性VWF沉默的疗效.

主要成果:

通过基因选择性VWF沉默,成功地改善了VWD模型的表型.
在初步研究中,在没有增加出血风险的情况下,证明了血栓形成的减少.
VWF静音使VWF多元组合正常化,并增加VWD中的功能VWF水平.

结论:

基因选择性VWF沉默是一种可行和有效的策略,通过使VWF水平和组成正常化来治疗VWD.
这种方法显示了通过降低VWF水平而降低血栓风险的潜力,而不会诱导出血表型.
该评论还总结了在2025年ISTH大会上提出的其他新型VWD治疗方法.

关键词:

这是一种RNA干扰.小小的干扰RNA可以干扰RNA.血栓形成的原因是血栓形成.·威勒布兰德病是一种疾病.·威勒布兰德因素是什么

更多相关视频

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

相关概念视频

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...